Clinical trials: Hepatotoxicity
Acetaminophen Overdose
Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection
The primary purpose of this study is determine if a new formulation of Acetadote is at least as effective as the current formulation in the prevention and treatment of acetaminophen overdose related liver injury.
- Trial name
- NCT01118663
- Testing
- Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cumberland Pharmaceuticals
HIV Infections
Case-Control Viramune (Nevirapine) Toxicogenomics Study
Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.
- Trial name
- NCT00310843
- Testing
- Nevirapine
- Where
- 102 sites in United States, Argentina and 9 more
- Volunteers
- 889 people
- Sponsor
- Boehringer Ingelheim
Infection, Human Immunodeficiency Virus I
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
Dolutegravir (DTG) is recommended for both treatment-naïve and treatment-experienced, HIV infected adults and paediatric subjects aged 12 years and older and weighing at least 40 kg.
- Trial name
- NCT03327740
- Testing
- DTG based ARV regimen with ABC, DTG based ARV regimen without ABC, RAL or EGV based ARV regimens with ABC
- Volunteers
- 1 people
- Sponsor
- ViiV Healthcare
Breast Cancer
Liver Safety Under Upfront Arimidex vs Tamoxifen
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.
- Trial name
- HEART (NCT00537771)
- Testing
- Anastrozole, Tamoxifen
- Where
- 16 sites in China
- Volunteers
- 384 people
- Sponsor
- AstraZeneca
Hepatotoxicity, Tenosynovial Giant Cell Tumor
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™…
- Trial name
- NCT04635111
- Testing
- TURALIO™
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Daiichi Sankyo